Latest Breaking News On - Pursues strategic - Page 1 : comparemela.com

SQZ® AAC Phase 1 Trial Observed Best Overall Response (BOR) of Stable Disease or Better in 60 Percent (3 of 5) of Treated Patients, Including One Patient with a Confirmed Complete ResponseSQZ® eAPC Phase 1/2 Trial Monotherapy Observed BOR of Stable Disease in 40 Percent (8 of 20) of Treated PatientsReduced Workforce.

Howard bernsteinBiotechnologies companyExchange commissionManagement teamSociety for immunotherapy of cancerCompany annual report on formObserved best overall responseStable diseaseTreated patientsIncluding one patientConfirmed completeCost reduction initiativesOngoing operating expenses whilePursues strategicInterim chief executive officerRecent portfolio